Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Novartis last week asked the FDA not to approve any generic copies of its heart failure drug Entresto before its exclusivity period ends in February 2024, citing labeling concerns. The agency denied a similar request from the drugmaker in April. For the treatment of heart failure, Entresto holds covered or better status for virtually all covered lives (99%) under the pharmacy benefit. 66.3% of insured lives have preferred access to Entresto without utilization management restrictions. The drug will likely face heavy competition, with at least 18 generic versions in development.

SOURCE: MMIT Analytics, as of 9/19/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 24

Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today